Phase II trial of 9-Aminocamptothecin administered as a 72-hour continuous infusion in metastatic colerectal carcinoma

Journal of Clinical Oncology

Volumn 15, Issue 8, 1997, Pages 2905-2909

  Pazdur, Richard ^a   Diaz Canton, Enrique ^a   Ballard, W Perry ^a   Bradof, James E ^a   Graham, Suzanne ^a   Arbuck, Susan G ^a   Abbruzzese, James L ^a   Winn, Rodger ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

9 AMINOCAMPTOTHECIN; NSC 603071; UNCLASSIFIED DRUG;

ADULT; AGED; ANEMIA; ANTINEOPLASTIC ACTIVITY; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; COLORECTAL CARCINOMA; CONTINUOUS INFUSION; DOSE TIME EFFECT RELATION; FATIGUE; HUMAN; HUMAN CELL; HUMAN TISSUE; INTRAVENOUS DRUG ADMINISTRATION; NAUSEA; NEUTROPENIA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; SCORING SYSTEM; STOMATITIS; VOMITING;

EID: 0030856927     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.1997.15.8.2905     Document Type: Article

References (27)

1. Zijlstra JG, De Jong S, DeVries EG, et al: Topoisomerases, new targets in cancer chemotherapy. Med Oncol Tumor Pharmacother 7:11-18, 1990
2. Gottlieb JA, Guarino AM, Call JB, et al: Preliminary pharmacologic and clinical evaluation of camptothecin sodium (NSC 100880). Cancer Chemother Rep 54:461-470, 1990
3. Muggia FM, Creaven PJ, Hansen HH, et al: Phase I clinical trial of weekly and daily treatment with camptothecin (NSC 100880): Correlation with preclinical studies. Cancer Chemother Rep 54:515-521, 1972
4. Gottlieb JA, Luce JK: Treatment of malignant melanoma with camptothecin (NSC-100880) Cancer Chemother Rep 56:103-105, 1972
5. Giovanella BC, Stehlin JS, Wall ME, et al: DNA topoisomerase I targeted chemotherapy of human colon cancer in xenografts. Science 246:1046-1048, 1989
6. Husain L, Mohler JL, Seigler HF, et al: Elevation of topoisomerase I messenger RNA, protein, and catalytic activity in human tumors: Demonstration of tumor-type specificity and implications for cancer chemotherapy. Cancer Res 54:539-546, 1994
7. Shimada Y, Yoshino M, Wakui A, et al: Phase II study of CPT-11, a new camptothecin derivative in metastatic colorectal cancer. J Clin Oncol 11:909-913, 1993
8. Conti JA, Kemeny NE, Saltz LB, et al: Irinotecan is an active agent in untreated patients with metastatic colorectal cancer. J Clin Oncol 14:709-715, 1996
9. Rothenberg ML, Eckardt JR, Kuhn JG, et al: Phase II trial of irinotecan in patients with progressive or rapidly recurrent colorectal cancer. J Clin Oncol 14:1128-1135, 1996
10. Tanizawa A, Pommier Y: Topoisomerase I inhibition, DNA damage and cytotoxicity induced by camptothecin derivatives in clinical trials. Proc Am Assoc Cancer Res 34:329, 1993 (abstr)
11. Johnson RK, McCabe FL, Gallagher G: Comparative efficacy of topotecan, irinotecan, camptothecin, and 9-AC in preclinical tumor models. Ann Oncol 3:85, 1992 (suppl, abstr)
12. Giovanella BP, Hinz HR, Kozielski AJ, et al: Complete growth inhibition of human cancer zenografts in nude mice by treatment with 20-(S)-camptothecin. Cancer Res 51:3052-3055, 1991
13. Bantazis P, Early JA, Kozielski AJ, et al: Regression of human breast carcinoma tumors in immunodeficient mice treated with 9-nitrocampthotecin: Differential response of nontumorigenic and tumorigenic human breast cells in vitro. Cancer Res 53:1577-1582, 1993
14. Hochster H, Potmesil M, Liebes J, et al: A phase I study of 9-amino-camptothecin (9-AC) by prolonged infusion to 21 days. Ann Oncol 7:130, 1996 (suppl 1, abstr)
15. Rubin E, Wood V, Bharti A, et al: A phase I and pharmacokinetic study of a new camptothecin derivative, 9-aminocamptothecin. Clin Cancer Res 1:269-276, 1995
16. Dahut W, Harold N, Takimoto C, et al: Phase I and pharmacologic study of 9-aminocamptothecin given by 72-hour infusion in adult cancer patients. J Clin Oncol 14:1236-1244, 1996
17. Ajani JA, Welch SR, Raber MN, et al: Comprehensive criteria for assessing therapy-induced toxicity. Cancer Invest 8:147-159, 1990
18. Gehan EA: The determination of the number of patients required in a follow-up trial of a new chemotherapeutic agent. J Chron Dis 13:346-353, 1961
19. Camptosar Package Insert. Kalamazoo, MI, Upjohn-Pharmacia, June 1996
20. Saltz L, Kemeny N, Soignet S, et al: A phase II sudy of 9-aminocamptothecin (9AC) in patients with fluorouracil (FU) refractory colorectal cancer. Proc Am Soc Clin Oncol 15:204, 1996 (abstr)
21. Wani MC, Nicholas AW, Manikumar G, Wall ME: Plant antitumor agents. Total synthesis and antileukemic activity of ring A substituted camptothecin analogues. Structure-activity correlations. J MedChem 30:1774-1779, 1987
22. Tsuruo T, Matsuzaki T, Matsushita M, et al: Antitumor activity of CPT-11, a new derivative of camptothecin, against pleiotropic drug resistant tumors in vitro and in vivo. Cancer Chemother Pharmacol 21:71-74, 1988
23. Houghton PJ, Cheshire PJ, Hallman JC, et al: Therapeutic efficacy of the topoisomerase 1 inhibitor 7-ethyl-10-(4-[1-piperidino]-l-piperidino)-carbonyloxy-camptothecin against human tumor xenografts: Lack of cross-resistance in vivo in tumors with acquired resistance to the topoisomerase I inhibitor 9-dimethylaminomethyl-10-hydroxycamptothecin. Cancer Res 53:2823-2829, 1993
24. Jaxel C, Kohn KW, Wani MC, et al: Structure-activity study of the actions of camptothecin derivatives on mammalian topoisomerase I: Evidence for a specific receptor site and relation to antitumor activity. Cancer Res 49:1465-1469, 1989
25. Vokes EE, Ansari R, Minami H, et al: A phase n and pharmacological study of 9-amino-camptothecin (9-AC) in advanced non-small cell lung cancer (NSCLC). Ann Oncol 7:130, 1996 (suppl 1, abstr)
26. Wilson WH, Pearson D, Humphrey R, et al: Phase II and dose escalation study ± G-CSF of 9-amino-camptothecin (9-AC) in relapsed lymphoma. Ann Oncol 7:131, 1996 (suppl 1, abstr)
27. Takimoto CH, Dahut W, Harold N, et al: A phase I trial of a prolonged infusion of 9-aminocamptothecin (9-AC) in adult patients with solid tumors. Proc Am Soc Clin Oncol 15:488, 1996 (abstr 1554)